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Methods. During 6-year period, adult patients with neutropenia who met probable or proven IPA by the EORTC criteria were retrospectively enrolled. IRIS was defined as new appearance or worsening of radiologic pulmonary findings temporally related to neutrophil recovery with evidence of a decrease 50% in serum galactomannan index titers.
Results. Of 150 patients, 35 (23%, 95% CI 17% -31%) developed IRIS during neutrophil recovery. IRIS was associated with shorter neutropenic period, controlled underlying hematologic disease, less immunosuppressant use, and voriconazole use (table). The 30-and 90-day mortalities were lower in patients with IRIS than those with non-IRIS (table). In the subgroup analysis of 53 patients who had progressive disease during the neutrophil recovery, 35 (66%, 95% CI 53% -77%) were classified as IRIS group. The 30-and 90-day mortalities was higher in patients with non-IRIS who had progressive disease during the neutrophil recovery than in those with IRIS (9% vs 39%, P = 0.02 and 31% vs 72%, P = 0.005, respectively).
Clinical characteristics and outcomes of neutropenic patients with and without immune reconstitution inflammatory syndrome following initiation of antifungal therapy for invasvie pulmonary aspergillosis IRIS (n=35) Non-IRIS (n=115) P continued. Conclusion. IRIS occured in about one quarter of neutropenic patients with IPA, was associated with voriconazole use. In addition, it appears to be a good prognostic factor.
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